AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

SubscribeContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

11 Aug
AHFS Drug Information logo
AHFS August 2020 Update

This update contains 2 new monographs, 12 revised monographs and 1 discontinued monograph.

New monographs: Capmatinib; Ripretinib

Revised monographs: Brentuximab; Sofosbuvir; Ledipasvir and Sofosbuvir; Ixekizumab; Sofosbuvir and Velpatasvir; Bictegravir, Emtricitabine, and Tenofovir Alafenamide; Romosozumab-aqqg; Bremelanotide; Selinexor; Remdesivir; Chloroquine; Hydroxychloroquine

Discontinued monograph: Daclatasvir

14 Jul
AHFS Drug Information logo
AHFS July 2020 Update

This update contains 6 new monographs, 15 revised monographs and 1 new MedWatch alert.

New monographs: Pemigatinib; Sacituzumab Govitecan-Hziy; Remdesivir; Tucatinib; Lemborexant; Opicapone

Revised monographs: Mifepristone; Propofol; Tegaserod; Ivermectin; Sapropterin; Abiraterone; Alemtuzumab; Ocrelizumab; Elagolix; Siponimod; Darolutamide; Tenapanor; Neostigmine; Pyridostigmine; Digoxin Immune Fab

New MedWatch alert on the following monograph: Ivermectin

09 Jun
AHFS Drug Information logo
AHFS June 2020 Update

This update contains 4 new monographs, 25 revised monographs and 1 new MedWatch alert.

New monographs: Crotalidae Immune F(ab’)2 (Equine); Osilodrostat; Ozanimod; Selumetinib

Revised monographs: Nitric Oxide; Crotalidae Polyvalent Immune Fab; Epoprostenol; Asparaginase (Erwinia chrysanthemi; Crofelemer; Elbasvir and Grazoprevir; Palbociclib; Olaratumab; Ribociclib; Sofosbuvir, Velpatasvir, and Voxilaprevir; Glecaprevir and Pibrentasvir; Abemaciclib; Triclabendazole; Calaspargase Pegol-mknl; Erdafitinib; Chloroquine; Hydroxychloroquine; Carbamide Peroxide; Ascorbic Acid; RaNITIdine; Pentostatin; Pegaspargase; Antineoplastic Agents; Antitoxins, Immune Globulins, Toxoids, and Vaccines; Miscellaneous Therapeutic Agents

New MedWatch alert on the following monograph: RaNITIdine

12 May
AHFS Drug Information logo
AHFS May 2020 Update

This update contains 5 new monographs, 38 revised monographs, 1 discontinued monograph and 3 new MedWatch alerts.

New monographs: Isatuximab-irfc; Rimegepant; Bempedoic Acid; Eptinezumab-jjmr; Cenobamate.

Revised monographs: Sirolimus; Montelukast; Lopinavir and Ritonavir; Nitric Oxide; Pregabalin; Lacosamide; Tocilizumab; Lorcaserin; Sarilumab; Patisiran; Mogamulizumab-kpkc; Doravirine; Doravirine, Lamivudine, and Tenofovir Disoproxil; Inotersen; Moxetumomab Pasudotox-tdfk; Baloxavir; Cladribine; Indomethacin; Ibuprofen; Orphenadrine; Chloroquine; Hydroxychloroquine; Chlorzoxazone; Phytonadione; MethylPREDNISolone; Captopril; Corticosteroids General Statement; Miotics General Statement; Diflunisal; CloZAPine; Cladribine; Gabapentin; Dalteparin; Topiramate; Valsartan; Azithromycin; Zanamivir; Oseltamivir.

Discontinued monographs: Ambenonium.

New MedWatch alerts on the following monographs: Montelukast; Lorcaserin; CloZAPine.

14 Apr
AHFS Drug Information logo
AHFS April 2020 Update

This update contains 8 new monographs and 7 revised monographs.

New monographs: Avapritinib; Ferric Derisomaltose; Antihemophilic Factor (recombinant), Glycopegylated-exei; Teprotumumab-trbw; Tazemetostat; Lasmiditan; Lumateperone; Cefiderocol.

Revised monographs: valGANciclovir; Eravacycline; Omadacycline; Metaxalone; Cyclobenzaprine; Carisoprodol; Methocarbamol.

10 Mar
AHFS Drug Information logo
AHFS March 2020 Update

This update contains 8 new monographs, 15 revised monographs, 2 discontinued monographs and 1 new MedWatch alert.

New monographs: Voxelotor; Givosiran; Enfortumab Vedotin-ejfv; Afamelanotide; Golodirsen; Ubrogepant; Imipenem, Cilastatin, and Relebactam; Fam-Trastuzumab Deruxtecan-nxki

Revised monographs: Dexmedetomidine; Mifepristone; Pregabalin; Sapropterin; Ocrelizumab; Durvalumab; Lutetium Lu 177 Dotatate; Pegvaliase-pqpz; Plazomicin; Iobenguane I 131; Phentolamine; EPINEPHrine; Loperamide; Misoprostol; Gabapentin

Discontinued monographs: daclizumab; dipivefrin

New MedWatch alerts on the following monographs: Pregabalin, Gabapentin

View more View all content updates